CLINICAL TRIAL article
Front. Vet. Sci.
Sec. Veterinary Neurology and Neurosurgery
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1598311
This article is part of the Research TopicEpilepsy in Veterinary Science - Volume IIView all 8 articles
Application of a novel three-day repetitive transcranial magnetic stimulation protocol for the treatment of drug-resistant epilepsy in dogs: single-blinded randomised sham-controlled clinical trial
Provisionally accepted
- University of Veterinary Medicine Hannover, Hanover, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
While the efficacy of repetitive transcranial magnetic stimulation (rTMS) has been explored in humans and, to a lesser extent, in dogs with epilepsy, further clinical studies are required to assess the potential antiseizure effect of this non-invasive neurostimulation technique. The objective was to assess the antiseizure effect and safety of a novel three-day rTMS protocol in dogs with drugresistant idiopathic epilepsy. A single-blinded, randomized, sham-controlled clinical trial was conducted by randomly allocating twenty dogs with drug-resistant idiopathic epilepsy or epilepsy of unknown origin into active (n=10) or sham (n=10) rTMS. The monthly seizure frequency (MSF), monthly seizure day frequency (MSDF), and number of cluster seizures (CS) were recorded and comparisons between the two groups were analysed. The safety of the rTMS protocol was also evaluated. Statistically significant differences were identified between the groups in median MSF (active, 8 [0-24]; sham, 17 ; p = 0.04), MSDF (active, 8 [0-24]; sham, 11 [6-23]; p = 0.04), and number of CS (active, 10 [5-23]; sham, 16 [10-25]; p = 0.005). No adverse events were reported. The current protocol indicates that active rTMS is safe, can reduce seizure frequency, and prevent CS in dogs with drug-resistant idiopathic epilepsy or epilepsy of unknown origin. An "one-size-fits-all" rTMS protocol for epilepsy in dogs is likely to provide suboptimal outcomes because the effect of rTMS is highly dependent on the duration and parameters of stimulation as well as individual variability. Therefore, future studies are needed to explore further specific stimulation parameters so they can be better tailored to the individual dog.
Keywords: Seizures, Dogs, Refractory, Management, neurostimulation
Received: 22 Mar 2025; Accepted: 16 Jul 2025.
Copyright: © 2025 Charalambous, Hünting, Meyerhoff, Twele, Meller and Volk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Marios Charalambous, University of Veterinary Medicine Hannover, Hanover, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.